Omar Krad
Ophthalmology · Mission Viejo, CANPI 1669635132
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Alcon at 33.7% of the total. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $101.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$9K
- Glaukos Corporation$6K
- AbbVie$2K
- Rxsight Inc$2K
- Bausch & Lomb Americas Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- plus $5K from 20 others
What the payments were for
- Consulting fees$6,80026%
- Speaking & faculty fees$6,65125%
- Travel & lodging$9514%
- Food & beverage$11,81945%
- Education$1130%
- Gifts$1661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 55 | $8,928 |
| Glaukos Corporation | 11 | $6,077 |
| AbbVie(2 entities) | 75 | $1,910 |
| Rxsight Inc | 8 | $1,562 |
| Bausch & Lomb Americas Inc. | 18 | $1,375 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $1,373 |
| Amgen(2 entities) | 20 | $1,030 |
| Aerie Pharmaceuticals, Inc. | 12 | $687 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $643 |
| Sun Pharmaceutical Industries Inc. | 9 | $455 |
| Oyster Point Pharma, Inc. | 4 | $438 |
| Sight Sciences, Inc. | 7 | $352 |
| Beaver-visitec International, Inc. | 2 | $214 |
| Microsurgical Technology, Inc. | 1 | $209 |
| Carl Zeiss Meditec USA, Inc. | 1 | $145 |
| Astellas Pharma US Inc | 1 | $134 |
| ANI Pharmaceuticals, Inc. | 1 | $125 |
| Kala Pharmaceuticals, Inc. | 1 | $124 |
| Tarsus Pharmaceuticals, Inc. | 1 | $120 |
| Novartis | 5 | $115 |
| Apellis Pharmaceuticals, Inc. | 1 | $115 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $110 |
| Shire North American Group Inc | 5 | $95 |
| Biotronik Inc. | 1 | $69 |
| Dompe US, Inc. | 2 | $54 |
| Ocular Therapeutix, Inc. | 2 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$1,313
- RXSIGHT INJECTOR CARTRIDGE$1,313
- RXSIGHT INJECTOR HANDPIECE$1,313
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,313
- LIGHT ADJUSTABLE LENS (LAL)$1,200
- Tecnis 1-piece IOL$900
- Tecnis 3-piece IOL$900
- Tecnis Symphony IOL$900
- Tecnis Symphony Toric IOL$900
- Rhopressa$857
- Rocklatan$857
- TEPEZZA$494
- enVista Aspire IOL$372
- TENEO$372
- STELLARIS ELITE$372
- TYRVAYA$372
- DURYSTA$233
- CEQUA$231
- VYZULTA$222
- Clareon PanOptix Pro$145
How this compares
$26,500 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 153 | $71,033 |
| VyzultaLatanoprostene Bunod | 97 | $32,150 |
| XiidraLifitegrast | 28 | $30,499 |
| RestasisCyclosporine | 34 | $28,290 |
| Cyclosporine | 47 | $12,267 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $11,020 |
| BesivanceBesifloxacin Hcl | 48 | $10,514 |
| Difluprednate | 119 | $9,877 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 72 | $9,523 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $6,759 |
| Brinzolamide | 30 | $5,742 |
| Prednisolone Acetate | 183 | $5,273 |
| BromsiteBromfenac Sodium | 16 | $4,217 |
| MoxifloxacinMoxifloxacin Hcl | 216 | $4,030 |
| Travoprost | 23 | $3,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $1,910 | $110,344221 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $1,375 | $62,649125 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Loteprednol Etabonate | $643 | $11,97360 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $687 | $6,75914 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $455 | $4,21716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Mission Viejo
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.